198 related articles for article (PubMed ID: 28149280)
1. The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia.
Au ED; Desai AP; Koniaris LG; Zimmers TA
Front Physiol; 2016; 7():682. PubMed ID: 28149280
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
3. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma.
Prado CM; Bekaii-Saab T; Doyle LA; Shrestha S; Ghosh S; Baracos VE; Sawyer MB
Br J Cancer; 2012 May; 106(10):1583-6. PubMed ID: 22510747
[TBL] [Abstract][Full Text] [Related]
6. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.
Puppa MJ; Gao S; Narsale AA; Carson JA
FASEB J; 2014 Feb; 28(2):998-1009. PubMed ID: 24145720
[TBL] [Abstract][Full Text] [Related]
7. Obesity worsens mitochondrial quality control and does not protect against skeletal muscle wasting in murine cancer cachexia.
Cardaci TD; VanderVeen BN; Bullard BM; McDonald SJ; Unger CA; Enos RT; Fan D; Velázquez KT; Frizzell N; Spangenburg EE; Murphy EA
J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):124-137. PubMed ID: 38062911
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer-derived extracellular vesicles induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway.
Hu W; Ru Z; Zhou Y; Xiao W; Sun R; Zhang S; Gao Y; Li X; Zhang X; Yang H
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Aug; 1864(8):1091-1102. PubMed ID: 31002945
[TBL] [Abstract][Full Text] [Related]
9. Ameliorating cancer cachexia by inhibiting cancer cell release of Hsp70 and Hsp90 with omeprazole.
Liu Z; Xiong J; Gao S; Zhu MX; Sun K; Li M; Zhang G; Li YP
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):636-647. PubMed ID: 34729960
[TBL] [Abstract][Full Text] [Related]
10. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.
Chiappalupi S; Sorci G; Vukasinovic A; Salvadori L; Sagheddu R; Coletti D; Renga G; Romani L; Donato R; Riuzzi F
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):929-946. PubMed ID: 32159297
[TBL] [Abstract][Full Text] [Related]
11. β‑carotene attenuates muscle wasting in cancer cachexia by regulating myogenesis and muscle atrophy.
Kim Y; Oh Y; Kim YS; Shin JH; Lee YS; Kim Y
Oncol Rep; 2024 Jan; 51(1):. PubMed ID: 37975253
[TBL] [Abstract][Full Text] [Related]
12. The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.
Bohnert KR; Goli P; Roy A; Sharma AK; Xiong G; Gallot YS; Kumar A
Mol Cell Biol; 2019 Aug; 39(15):. PubMed ID: 31138662
[TBL] [Abstract][Full Text] [Related]
13. Ursolic Acid Alleviates Cancer Cachexia and Prevents Muscle Wasting via Activating SIRT1.
Tao W; Ouyang Z; Liao Z; Li L; Zhang Y; Gao J; Ma L; Yu S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190306
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
15. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
16. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.
Bonetto A; Aydogdu T; Kunzevitzky N; Guttridge DC; Khuri S; Koniaris LG; Zimmers TA
PLoS One; 2011; 6(7):e22538. PubMed ID: 21799891
[TBL] [Abstract][Full Text] [Related]
17. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
18. Exosomal IL-8 derived from Lung Cancer and Colon Cancer cells induced adipocyte atrophy via NF-κB signaling pathway.
Xiong H; Ye J; Xie K; Hu W; Xu N; Yang H
Lipids Health Dis; 2022 Dec; 21(1):147. PubMed ID: 36581870
[TBL] [Abstract][Full Text] [Related]
19. Morin suppresses cachexia-induced muscle wasting by binding to ribosomal protein S10 in carcinoma cells.
Yoshimura T; Saitoh K; Sun L; Wang Y; Taniyama S; Yamaguchi K; Uchida T; Ohkubo T; Higashitani A; Nikawa T; Tachibana K; Hirasaka K
Biochem Biophys Res Commun; 2018 Dec; 506(4):773-779. PubMed ID: 30389140
[TBL] [Abstract][Full Text] [Related]
20. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia.
AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
